These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 21503391)
1. Impact of chronic kidney disease on the efficacy of drug-eluting stents: long-term follow-up study. Osório Gomes V; Blaya P; Lasevitch R; Oliveira D; Hickmann P; Smidt L; Polanczyk C; Caramori P Arq Bras Cardiol; 2011 May; 96(5):346-51. PubMed ID: 21503391 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. Tsai TT; Messenger JC; Brennan JM; Patel UD; Dai D; Piana RN; Anstrom KJ; Eisenstein EL; Dokholyan RS; Peterson ED; Douglas PS J Am Coll Cardiol; 2011 Oct; 58(18):1859-69. PubMed ID: 22018296 [TBL] [Abstract][Full Text] [Related]
3. Impact of chronic kidney disease on long-term clinical outcomes after percutaneous coronary intervention with drug-eluting or bare-metal stents. Kersting S; Grumann T; Hummel J; Hauschke D; Bode C; Hehrlein C Crit Pathw Cardiol; 2012 Sep; 11(3):152-9. PubMed ID: 22825536 [TBL] [Abstract][Full Text] [Related]
4. Long-term benefits and risks of drug-eluting compared to bare-metal stents in patients with versus without chronic kidney disease. Wanitschek M; Pfisterer M; Hvelplund A; De Servi S; Bertel O; Jeger R; Rickenbacher P; Iversen A; Jensen JS; Galatius S; Kaiser C; Alber H; Int J Cardiol; 2013 Oct; 168(3):2381-8. PubMed ID: 23453439 [TBL] [Abstract][Full Text] [Related]
6. Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial. Crimi G; Leonardi S; Costa F; Adamo M; Ariotti S; Valgimigli M Int J Cardiol; 2016 Jun; 212():110-7. PubMed ID: 27038714 [TBL] [Abstract][Full Text] [Related]
7. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. Baber U; Giustino G; Sartori S; Aquino M; Stefanini GG; Steg PG; Windecker S; Leon MB; Wijns W; Serruys PW; Valgimigli M; Stone GW; Dangas GD; Morice MC; Camenzind E; Weisz G; Smits PC; Kandzari D; Von Birgelen C; Mastoris I; Galatius S; Jeger RV; Kimura T; Mikhail GW; Itchhaporia D; Mehta L; Ortega R; Kim HS; Kastrati A; Chieffo A; Mehran R JACC Cardiovasc Interv; 2016 Jan; 9(1):28-38. PubMed ID: 26762908 [TBL] [Abstract][Full Text] [Related]
8. Randomized Comparison of Xience V and Multi-Link Vision Coronary Stents in the Same Multivessel Patient With Chronic Kidney Disease (RENAL-DES) Study. Tomai F; Ribichini F; De Luca L; Petrolini A; Ghini AS; Weltert L; Spaccarotella C; Proietti I; Trani C; Nudi F; Pighi M; Vassanelli C Circulation; 2014 Mar; 129(10):1104-12. PubMed ID: 24357403 [TBL] [Abstract][Full Text] [Related]
9. Short- and long-term benefits of drug-eluting stents compared to bare metal stents even in treatment for large coronary arteries. Yoshida T; Sakata K; Nitta Y; Taguchi T; Kaku B; Katsuda S; Shimojima M; Gamou T; Nakahashi T; Konno T; Kawashiri MA; Yamagishi M; Hayashi K Heart Vessels; 2016 May; 31(5):635-42. PubMed ID: 25758470 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis. Almalla M; Pross V; Marx N; Hoffmann R Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414 [TBL] [Abstract][Full Text] [Related]
11. Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease. Siddiqi OK; Smoot KJ; Dufour AB; Cho K; Young M; Gagnon DR; Ly S; Temiyasathit S; Faxon DP; Gaziano JM; Kinlay S Heart; 2015 Oct; 101(19):1569-76. PubMed ID: 26209334 [TBL] [Abstract][Full Text] [Related]
12. Major adverse cardiovascular events after drug-eluting stent implantation in patients with single chronic total occlusion: a single-center registry. Gilis-Siek N; Fijalkowski M; Jaguszewski M; Targonski R; Strozyk A; Cackowska M; Masiewicz E; Skarzynski P; Burakowski S; Chmielecki M; Lewicki L; Dubaniewicz W; Gruchala M; Ciecwierz D; Rynkiewicz A J Invasive Cardiol; 2013 Nov; 25(11):567-72. PubMed ID: 24184890 [TBL] [Abstract][Full Text] [Related]
13. Drug-Eluting vs Bare-Metal Stents in Patients With Chronic Kidney Disease and Coronary Artery Disease: Insights From a Systematic Review and Meta-Analysis. Volodarskiy A; Kumar S; Pracon R; Sidhu M; Kretov E; Mazurek T; Bockeria O; Kaul U; Bangalore S J Invasive Cardiol; 2018 Jan; 30(1):10-17. PubMed ID: 28915510 [TBL] [Abstract][Full Text] [Related]
14. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents. Kandzari DE; Leon MB; Meredith I; Fajadet J; Wijns W; Mauri L JACC Cardiovasc Interv; 2013 May; 6(5):504-12. PubMed ID: 23602459 [TBL] [Abstract][Full Text] [Related]
15. Impact of Mild-to-Moderate Chronic Kidney Disease on One Year Outcomes after Percutaneous Coronary Intervention. Grandjean-Thomsen NL; Marley P; Shadbolt B; Farshid A Nephron; 2017; 137(1):23-28. PubMed ID: 28478459 [TBL] [Abstract][Full Text] [Related]
16. Short and long term outcome of percutaneous coronary intervention with drug eluting stent and bare metal stent in patients with chronic kidney disease. Resmini C; Di Cuia M; Ballocca F; D'Ascenzo F; Bollati M; Moretti C; Omedè PL; Sciuto F; Gaita F; Sheiban I Minerva Cardioangiol; 2012 Dec; 60(6):573-80. PubMed ID: 23147435 [TBL] [Abstract][Full Text] [Related]
17. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials. Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419 [TBL] [Abstract][Full Text] [Related]
18. One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent. Barthelemy O; Helft G; Silvain J; Bellemain-Appaix A; Beygui F; Choussat R; Berman E; Collet JP; Montalescot G; Metzger JP; Le Feuvre C Arch Cardiovasc Dis; 2011 Dec; 104(12):604-10. PubMed ID: 22152512 [TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of drug eluting stent in patients with ST elevation myocardial infarction undergoing primary angioplasty. Romano M; Buffoli F; Tomasi L; Corrado L; Ferrari MR; Zanini R Catheter Cardiovasc Interv; 2008 May; 71(6):759-63. PubMed ID: 18412066 [TBL] [Abstract][Full Text] [Related]
20. First-generation versus second-generation drug-eluting stents in patients with chronic kidney disease: a systematic review and meta-analysis. Gao WD; Ma M; Zhang GX; Zhang XF; Sun G Postgrad Med; 2019 Jan; 131(1):43-51. PubMed ID: 30422052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]